Please login to the form below
Data by
13
Revenue 2014Teva
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Teva's 2013 sales performance.
Teva to cut 7000 jobs, close 15 manufacturing sites
Teva to cut 7000 jobs, close 15 manufacturing sites. Missed second-quarter sales expectations prompt the cutbacks. ... Due to steep share price declines, Teva ended the second quarter with a market valuation below its debt.
Raffi Asadorian joins AcelRx Pharmaceuticals
He has also held roles at PircewaterhouseCoopers and Barr, which was later acquired by Teva Pharmaceuticals.
After MYSTIC setback, FDA gives some comfort to AZ
The news comes after AZ's chief executive Pascal Soriot re-affirmed his commitment to the company despite a rumoured move to Teva, saying he intends to stay at least until
UK appoints pharma veteran to 'streamline' NHS costs
Oldfield has more than 25 years’experience within the healthcare industry, he currently serves as chief operating officer for Procter &Gamble and Teva’s Geneva-based consumer health joint venture. ... His extensive experience in senior pharmaceutical
Shock for AZ as MYSTIC trial stumbles at first hurdle
The MYSTIC setback may well re-ignite speculation about the future of Soriot, who was rumoured to be planning to leave the company and take the helm of Israeli drugmaker Teva
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| CNS revenue 2014 |
|---|
| 1: Pfizer |
| 2: Biogen Idec |
| 3: Novartis |
| 4: Otsuka |
| 5: Teva |
| 6: Johnson & Johnson |
| 7: Lilly |
| 8: Merck KGaA |
| 9: AstraZeneca |
| 10: Shire |
| 11: Bristol-Myers Squibb |
| 12: UCB |
| 13: Lundbeck |
| 14: Eisai |
| 15: GlaxoSmithKline |
| 16: Sanofi |
| 17: Mylan |
| 18: Indivior |
| 19: Actavis |
| 20: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
- Head of Communications - Based Cambridge
-
Excellent Basic and Flex Benefits
-
Brand Manager
-
Competitive salary and package
- Senior Account Manager/ Account Director – Pharma and Life Scien...
-
Competitive Salary
- JAM – Med Comms – Independent Agency
-
Salary TBC
- Account Executive - Pharma and Life Sciences Brighton or Maccles...
-
Competitive Salary
- Principal Medical Writer, Medical Education Agency
-
£46, 000 – £56, 000 benefits
- Freelance Medical Copywriter, Healthcare Advertising Agency
-
according to skills and experience
- Account Manager – Healthcare Advertising
-
Salary TBC
-
Editorial Director - BioScience
-
Competitive Salary
- Account Manager, Medical Communications
-
£30, 000-£40, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Principal Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Novartis trial marks ResearchKit first in MS
- Samsung deal with Takeda looks beyond biosimilars
- Ocrevus off to a flying start as Roche raises 2017 forecasts
- NICE set to reject Pfizer's leukaemia drug Besponsa
- Biocon backs away from biosimilar filings in Europe
- Astellas extends phase III programme for Rydapt rival gilteritinib
- Hugh Cole joins Jounce Therapeutics as chief business officer
- PharmaLex appoints Dr Adam King to its regulatory team
- The Pharma Wars Series
- Ironwood claims FDA OK for former AZ gout drug
- Astellas extends phase III programme for Rydapt rival gilteritinib
- What pharma marketers can learn from growth hacking?
PMHub
Pulsar
THE SCIENCE BEHIND CREATIVE RESULTS When science meets art there's chemistry. We simply add passion, positivity and a human warmth....
Latest intelligence
- The Pharma Wars Series
- The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
- What pharma marketers can learn from growth hacking?
- Growth hackers instinctively blend technical skills with creative thinking...
- The sound of silence puts the squeeze on generics and biosimilars
- Medicines for Europe vows to get governments talking to realise potential...
Quick links
Infographics
